Clinical Trial Update: Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia [Phase 4]

View source ↗

Summary

This Phase 4 trial compares Inclisiran (KJX839) vs placebo in adults with hypercholesterolemia on ongoing lipid-lowering therapy to assess efficacy, safety, tol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Inclisiran (KJX839) (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 4 | Status: COMPLETED | Results posted: 2026-04-14